The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis

• Main Authors: Elena Genovese (Author), Margherita Mirabile (Author), Sebastiano Rontauroli (Author), Stefano Sartini (Author), Sebastian Fantini (Author), Lara Tavernari (Author), Monica Maccaferri (Author), Paola Guglielmelli (Author), Elisa Bianchi (Author), Sandra Parenti (Author), Chiara Carretta (Author), Selene Mallia (Author), Sara Castellano (Author), Corrado Colasante (Author), Manjola Balliu (Author), Niccolò Bartalucci (Author), Raffaele Palmieri (Author), Tiziana Ottone (Author), Barbara Mora (Author), Leonardo Potenza (Author), Francesco Passamonti (Author), Maria Teresa Voso (Author), Mario Luppi (Author), Alessandro Maria Vannucchi (Author), Enrico Tagliafico (Author), Rossella Manfredini (Author), on behalf of the Mynerva (MYeloid NEoplasms Research Venture AIRC) (Author)
• Format: Book
• Published: MDPI AG, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Myelofibrosis (MF) is the Philadelphia-negative myeloproliferative neoplasm characterized by the worst prognosis and no response to conventional therapy. Driver mutations in <i>JAK2</i> and <i>CALR</i> impact on JAK-STAT pathway activation but also on the production of reacti...